SCHEMBL1483376

SCHEMBL1483376

COC(=O)c1ccc([N+](=O)[O-])s1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.55
CASP3 P42574 8/20 0.55
SENP8 Q96LD8 8/20 0.55
SENP7 Q9BQF6 8/20 0.55
SENP6 Q9GZR1 8/20 0.55
L3MBTL1 Q9Y468 8/20 0.55
CASP6 P55212 6/20 0.55
POLB P06746 6/20 0.55
CASP8 Q14790 5/20 0.55
CASP9 P55211 4/20 0.55
CASP7 P55210 3/20 0.55
HSP90AA1 P07900 2/20 0.54
MAPT P10636 2/20 0.54
LMNA P02545 6/20 0.54
SMN1; SMN2 Q16637 4/20 0.54
HTT P42858 3/20 0.54
TDP2 O95551 2/20 0.53
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
ATM Q13315 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11480640 0.81 ATM (0.55) ALDH1A1CASP3SENP8SENP7SENP6
SCHEMBL4684428 0.81 L3MBTL1 (0.69) ALDH1A1CASP3SENP8SENP7SENP6
SCHEMBL20464026 0.81 L3MBTL1 (0.48) ALDH1A1CASP3SENP8SENP7SENP6
SCHEMBL11460500 0.81 MITF (0.55) ALDH1A1CASP3SENP8SENP7SENP6
SCHEMBL218867 0.81 SMN1; SMN2 (0.53) ALDH1A1CASP3SENP8SENP7SENP6
Hydrochloric Acid SCHEMBL7036575 0.79 SMN1; SMN2 (0.51) ALDH1A1CASP3SENP8SENP7SENP6
SCHEMBL1937600 0.79 LMNA (0.54) ALDH1A1L3MBTL1POLBMAPTLMNA
SCHEMBL3268354 0.79 SMN1; SMN2 (0.61) ALDH1A1L3MBTL1POLBMAPTLMNA
SCHEMBL70027 0.78 NPSR1 (0.67) ALDH1A1L3MBTL1MAPTLMNASMN1; SMN2
SCHEMBL23529356 0.76 SMN1; SMN2 (0.53) ALDH1A1CASP3SENP8SENP7SENP6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116023359-B Synthesis method of aminothiophene compound and aminothiophene compound 上海泰坦科技股份有限公司 2024-08-02 CN disclosed
US-20240109917-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2024-04-04 US disclosed
EP-4267585-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS Actelion Pharmaceuticals Ltd (CH) 2023-11-01 EP disclosed
CN-116802184-A Pyrazolothiazole carboxamides and their use as PDGFR inhibitors 埃科特莱茵药品有限公司 2023-09-22 CN disclosed
CN-116023359-A Synthesis method of aminothiophene compound and aminothiophene compound 上海泰坦科技股份有限公司 2023-04-28 CN disclosed
US-20220281866-A1 5,8-DISUBSTITUTED-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL AND 5,8-DISUBSTITUTED-IMIDAZO[1,2-A]PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF ENTEROPEPTIDASE JANSSEN PHARMACEUTICA NV (BE) 2022-09-08 US disclosed
WO-2022136509-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2022-06-30 WO disclosed
WO-2021013742-A1 5,8-DISUBSTITUTED-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL AND 5,8-DISUBSTITUTED-IMIDAZO[1,2-A]PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF ENTEROPEPTIDASE JANSSEN PHARMACEUTICA NV (BE) 2021-01-28 WO disclosed
CN-105283443-B Hete rocyclic derivatives and application thereof 株式会社C&C新药研究所 2018-08-17 CN disclosed
CN-105283443-A Heterocyclic derivatives and use thereof C & C RES LAB 2016-01-27 CN disclosed
US-6051243-A USEFUL IN THE TOPICAL AND SYSTEMIC TREATMENT OF DERMATOLOGICAL CONDITIONS ASSOCIATED WITH A KERATINIZATION DISORDER, DERMATOLOGICAL CONDITIONS (AND THE LIKE) INCLUDING AN INFLAMMATORY AND/OR IMMUNOALLERGIC COMPONENT CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (FR) 2000-04-18 US disclosed
EP-0912175-A4 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO INC (US) 1999-09-08 EP disclosed
EP-0912175-A1 FIBRINOGEN RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 1999-05-06 EP disclosed
US-5854245-A Fibrinogen receptor antagonists MERCK & CO., INC. (US) 1998-12-29 US disclosed
CN-1192729-A Benzamide derivatives and their use as vasopressin antagonists FUJISAWA PHARMACEUTICAL CO (JP) 1998-09-09 CN disclosed
EP-0832061-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS VASOPRESSIN ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-04-01 EP disclosed
US-5709867-A TREATMENT OF DERMATOLOGICAL, RHEUMATIC, RESPIRATORY, CARDIOVASCULAR, AND OPHTHALMOLOGICAL DISORDERS CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) 1998-01-20 US disclosed
WO-1998000134-A1 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1998-01-08 WO disclosed
WO-1996041795-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS VASOPRESSIN ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-12-27 WO disclosed
US-4219482-A Process for preparing thiophene and furan derivatives LABAZ (FR) 1980-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220281866-A1 5,8-DISUBSTITUTED-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL AND 5,8-DISUBSTITUTED-IMIDAZO[1,2-A]PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF ENTEROPEPTIDASE TMPRSS15, DPP8, SI ALDH1A1 620/4885CASP3 820/4885SENP8 347/4885
US-20240109917-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS PDGFRA, PDGFRB, ABL1 ALDH1A1 916/4885CASP3 1874/4885SENP8 4200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.